Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 20/20 | 1.00 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22499237 | 0.97 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22498932 | 0.97 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499068 | 0.96 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499017 | 0.94 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499112 | 0.93 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22498903 | 0.93 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499027 | 0.92 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499163 | 0.92 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22499020 | 0.92 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22498871 | 0.92 | METTL3 (1.00) | METTL3METTL14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | claimed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | claimed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | claimed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | claimed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | claimed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20240277715-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LIMITED (GB) | 2024-08-22 | — | — | US | disclosed |
| EP-4346814-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | Storm Therapeutics Ltd (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230383292-A1 | TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY | THE GENERAL HOSPITAL CORPORATION | 2023-11-30 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| WO-2022254216-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | METTL3 1/4885METTL14 5/4885 |
| US-20230383292-A1 | TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY | METTL16, NSUN2, METTL3 | METTL3 3/4885METTL14 19/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | METTL3 1/4885METTL14 25/4885 |
| US-20240277715-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | FLT3, METTL3, TET2 | METTL3 2/4885METTL14 25/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | METTL3 1/4885METTL14 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.